Should a woman over 35 years old discontinue combined estrogen‑progestin oral contraceptive pills?

Should Women Over 35 Stop Taking Birth Control Pills?

Age 35 alone is not a reason to discontinue combined oral contraceptives; however, specific cardiovascular risk factors—particularly smoking—mandate an immediate switch to progestin-only or non-hormonal methods. 1, 2

Key Decision Points at Age 35

Smoking Status: The Critical Determinant

Combined estrogen-progestin contraceptives (pills, patches, rings) are absolutely contraindicated in all women ≥35 years who smoke, regardless of the number of cigarettes. 1, 2

• The relative risk of myocardial infarction rises to approximately 12.5-fold in smokers over 35 using combined contraception, especially those smoking >15-20 cigarettes daily 2, 3
• This contraindication applies to all routes of administration—oral, transdermal patches, and vaginal rings 1, 2
• Even light smoking (<15 cigarettes/day) does not make combined contraception acceptable; any smoking constitutes a contraindication 2
• The majority of coronary and cerebrovascular events in contraceptive users occur in women aged 35-40 years, with smoking as the key contributor 2, 3

Hypertension: Blood Pressure Thresholds Matter

Combined contraceptives should be avoided when blood pressure reaches or exceeds 140-160/90-100 mmHg. 1, 4

• Blood pressure measurement is the only mandatory clinical examination before prescribing combined contraception 1, 4
• For women <35 years on effective antihypertensive treatment with no complications or other cardiovascular risk factors, the contraindication is only relative 1, 4
• For women ≥35 years with hypertension, combined contraception is contraindicated regardless of treatment status 1, 4
• Hypertensive women using combined contraceptives experience markedly increased risk of stroke (OR 3.1-14.5) and myocardial infarction (OR 6-68) 4

Other Absolute Contraindications After Age 35

Combined contraception must be stopped immediately if any of the following develop: 1, 3

• Personal history of venous thromboembolism (deep vein thrombosis or pulmonary embolism) 1
• Personal history of arterial events (stroke, transient ischemic attack, coronary heart disease) 1, 3
• Migraine with aura or family history of premature cardiovascular events before age 50 1
• Documented thrombophilia (factor V Leiden, prothrombin mutation, protein C/S deficiency) 1
• Diabetes with vascular complications (nephropathy, advanced retinopathy, neuropathy) 1

Safe Alternatives for Women Over 35

Progestin-Only Methods: First-Line Hormonal Options

Progestin-only contraceptives carry no increased cardiovascular or thrombotic risk and can be used safely regardless of age, smoking status, or controlled hypertension. 1, 2, 4

• Progestin-only pills (desogestrel 75 mcg or norethindrone): No increase in stroke or myocardial infarction; venous thromboembolism relative risk 0.90 (95% CI 0.57-1.45) 2
• Levonorgestrel intrauterine device (IUD): >99% efficacy, no thrombosis risk, reduces heavy menstrual bleeding 2, 4
• Etonogestrel subdermal implant: >99% efficacy without estrogen-related cardiovascular risks 2, 4
• Depot medroxyprogesterone acetate (DMPA): Does not increase stroke risk, though requires careful follow-up 2

These methods remain safe even in women with:

• Uncontrolled hypertension (≥160/100 mmHg) 4
• Established cardiovascular disease 4
• Active smoking at any intensity 1, 2

Non-Hormonal Options

Copper IUD offers >99% efficacy with no hormonal or cardiovascular risk. 2

• Appropriate for all women over 35, including those with multiple cardiovascular risk factors 2
• Provides highly effective contraception without metabolic effects 2

When Combined Contraceptives May Continue After 35

Healthy, non-smoking women over 35 without cardiovascular risk factors can safely continue combined oral contraceptives. 5, 6, 7, 8

Required Criteria (All Must Be Present):

• No smoking history 1, 2
• Blood pressure <140/90 mmHg 1, 4
• No personal or first-degree family history of premature cardiovascular events 1
• No migraine with aura 1
• No diabetes, thrombophilia, or dyslipidemia 1
• No history of venous or arterial thromboembolism 1

Additional Benefits in This Population:

• Protection against unwanted pregnancy (which carries higher maternal and fetal complications after age 35) 2, 6
• Reduction in abnormal menstrual bleeding common during perimenopause 5, 6
• Continued protection against endometrial and ovarian cancer 6, 7, 8
• Prevention of bone loss 6
• Stable hormonal environment during perimenopausal fluctuations 5, 6

Critical Pitfalls to Avoid

Do not assume low-dose estrogen formulations (20 mcg ethinyl estradiol) are safer for women with contraindications—the same restrictions apply to all doses and routes. 2, 3

Do not consider transdermal patches or vaginal rings as safer alternatives for smokers or hypertensive women over 35—they carry identical cardiovascular risks. 1, 2

Do not delay switching to progestin-only methods when smoking continues or resumes, or when hypertension develops. 2, 4

Do not rely on FSH levels to determine when to stop contraception—no laboratory test can definitively confirm loss of fertility, and contraception should continue until menopause (median age 51 years). 2, 9

Duration of Contraceptive Use

Continue effective contraception until menopause or age 50-55 years. 2, 9

• Pregnancy remains possible throughout perimenopause and carries higher risks of hemorrhage, venous thromboembolism, maternal death, spontaneous abortion, stillbirth, and congenital anomalies 2
• FSH measurement is unreliable for determining fertility status in women using hormonal contraception 9

Practical Clinical Algorithm

1. At age 35, assess cardiovascular risk factors:

   • Smoking status (any amount = contraindication to combined methods) 1, 2
   • Blood pressure (≥140/90 mmHg = avoid combined methods) 1, 4
   • Personal or family history of thromboembolism or cardiovascular disease 1
   • Migraine pattern (aura = contraindication) 1
   • Diabetes, dyslipidemia, or thrombophilia 1

2. If any contraindication exists:

   • Discontinue combined contraception immediately 1, 2
   • Offer progestin-only pill, levonorgestrel IUD, etonogestrel implant, or copper IUD 2, 4

3. If no contraindications exist:

   • Combined contraception may continue with annual reassessment 5, 6, 7
   • Monitor blood pressure at each visit 1, 4
   • Counsel on smoking cessation and cardiovascular risk reduction 2, 3

4. Transition planning:

   • Continue contraception until age 50-55 or confirmed menopause 2, 9
   • Consider switching to hormone replacement therapy only after documented cessation of ovarian function 9